Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Green Cross Corp.
DescriptionA novel hybrid Fc (hyFc) fused erythropoietin (EPO)-hybrid Fc
Molecular Target Erythropoietin (EPO) receptor
Mechanism of ActionErythropoietin (EPO) receptor agonist
Therapeutic ModalityBiologic: Fusion protein
Latest Stage of DevelopmentPhase I
Standard IndicationAnemia
Indication DetailsTreat anemia
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today